AHCL Anlon Healthcare Q4 FY26 results (Jan–Mar 2026) and concall
AHCL reported strong financial growth for FY26, with significant increases in total income, EBITDA, and PAT, driven by strategic acquisitions and capacity expansion. However, Q4 FY26 PAT was lower due to increased operating costs and raw material price volatility. The company provided optimistic guidance for FY27 and FY28 revenue, while addressing concerns regarding working capital management and aiming for positive cash flow by FY27 end.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 4.0%, net profit down 33.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 24 | 9 | 49 | 33 | 52 +116% | 36 +280% | 51 +4% |
| EBITDA | 8 | 1 | 17 | 6 | 14 +83% | 12 +2017% | 15 −11% |
| Net profit | 3 | -2 | 17 | 4 | 9 +260% | 5 +307% | 11 −34% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
